Facts
- HQ
- United States
- Sectors
- Venture Capital and Private Equity Principals
- Employees
- 15
Recent coverage
Front-page news, podcasts and videos about Argonautic Ventures
Accipiter Bio raises $10.5M more to speed AI-designed multi-target protein drugs, expanding clinical pipeline
Seattle biotech Accipiter Bio raised an additional $10.5 million from existing investors to accelerate development of AI-designed multi-target protein therapeutics and expand its team and clinical pipeline. The company, now 22 people strong and partnered with Pfizer and Kite/Gilead, will use the funds to advance three to four programs—focusing mainly on immunology alongside oncology—after emerging from stealth last year with $12.7 million.
Seattle’s Accipiter Bio Raises $12.7M, Partners with Pfizer and Kite Pharma to Advance AI-Designed Multi-Target Protein Therapies
Seattle biotech startup Accipiter Biosciences, founded by researchers from Nobel laureate David Baker's lab, secured $12.7 million and partnerships with Pfizer and Kite Pharma to develop AI-designed multi-target proteins aiming to improve disease treatment efficacy and reduce clinical trial costs.
